Finerenone Cuts Albuminuria in Type 1 Diabetes with CKD

FINE-ONE extends finerenone's renoprotective signal into type 1 diabetes, providing the first randomized evidence for a nonsteroidal mineralocorticoid receptor antagonist in this previously untested population.

finerenonenonsteroidal mineralocorticoid receptor antagonisttype 1 diabeteschronic kidney diseasealbuminuriaUACRhyperkalemiaFINE-ONEphase 3 RCTnephrology Endocrinology / Obesity

Background Information

Semaglutide slashes kidney and heart risks in diabetes with kidney disease.

Patients with type 2 diabetes and chronic kidney disease face increased risks of kidney failure and cardiovascular death. Semaglutide reduced risk of major kidney disease events by 24%, cardiovascular events by 18%, and death by 20% compared to placebo. Semaglutide offers substantial benefits in reducing kidney and cardiovascular risks in this patient population, highlighting its role in treatment plans. Semaglutide significantly lowers kidney and cardiovascular risks in type 2 diabetes patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators

Citation: Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →